Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEHAW
Aesther Healthcare Acquisition
$0.01
+84.9%
$0.01
$0.06
$0.33
N/AN/A34,287 shs5,100 shs
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
-5.7%
$0.01
$0.00
$0.04
N/AN/A136,250 shs335,477 shs
LBPSW
4D pharma
$0.00
$0.04
$1.29
N/AN/A20,931 shsN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$0.68
+2.0%
$1.00
$0.59
$8.60
N/A0.56111,720 shs124,980 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEHAW
Aesther Healthcare Acquisition
0.00%+276.92%+38.03%+92.16%-75.62%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-5.66%-12.28%+26.58%+19.05%-7.41%
LBPSW
4D pharma
0.00%0.00%0.00%0.00%0.00%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
+2.04%-17.56%-51.01%-40.70%-83.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.399 of 5 stars
0.03.00.00.00.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
LBPSW
4D pharma
0.00
N/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
$522KN/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$85.67MN/AN/AN/A$7.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
-$13.93MN/A0.00N/AN/AN/AN/A8/21/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/A
LBPSW
4D pharma
N/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.05
1.02
0.75
CompanyEmployeesShares OutstandingFree FloatOptionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
LBPSW
4D pharma
N/AN/AN/ANot Optionable
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
773N/AN/AN/A

Recent News About These Companies

LakeShore Biopharma Co., Ltd (LSB) - Yahoo Finance
LakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial Approval
LakeShore Biopharma Co Ltd Ordinary Shares
LakeShore Biopharma Advances PIKA Rabies Vaccine Approval
LakeShore Biopharma Announces Leadership Transition
LakeShore Biopharma Achieves Nasdaq Compliance Milestone
LakeShore Biopharma Advances with Rabies Vaccine Trial

Media Sentiment Over Time

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.0098 +0.00 (+84.91%)
As of 08/1/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.01 0.00 (-5.66%)
As of 08/7/2025 03:56 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

LakeShore Biopharma stock logo

LakeShore Biopharma NASDAQ:LSB

$0.68 +0.01 (+2.04%)
Closing price 08/7/2025 03:58 PM Eastern
Extended Trading
$0.70 +0.03 (+4.29%)
As of 08/7/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.